🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If attacking multiple targets by using combinations is one way to address heterogeneity, why cannot we use four, five or more drugs? Because every time we add a drug, we also increase toxicities. We must test the safety and efficacy of any combo in a well designed clinical trial.

It was my pleasure and honor to have presented this study on behalf of my colleagues, patients and families!

Have a cool weekend! Scene from New Zealand

Nice summary of approved T-cell redirecting agents by Dr. Alvarez-Vallina #EHA2025 #mmsm #lymsm

Excited to share our Cancer Cell Cell Press article on the discovery of the IL-15 Receptor "Regulome". A technical tour-de-force from the Immunology, computational biology & functional genomics teams oNKo-innate Monash Biomedicine Discovery Institute

#BurnoutSurvey among heme professionals 🚨 N=1843 42% high emotional exhaustion 33% high depersonalization 50% burnout 67% low personal accomplishment Systemic factors > personal resilience It’s time to act ! European Hematology Association YoungEHA HemaSphere Journal (IF = 14.6)

CONGRESS | #EHA2025 | PRESENTATION Raul Cordoba, MD, PhD Fundación Jiménez Díaz discusses updated safety and efficacy results for patients with R/R MCL treated with sonrotoclax + zanubrutinib in the ongoing phase I BGB-11417-101 trial (N = 51). Sonrotoclax + zanubrutinib was well tolerated with

Dr. Anna Maria Frustaci presenting BTK degrader BGB-16674 CaDAnce-101 Ph1 R/R WM study at #EHA2025 Good safety profile. Antitumor activity seen (ORR 84.4%, VGPR 31.3%) with rapid decline of biomarkers, improvement of cytopenias and deepening of responses with time #wmsm

Sonrotoclax + zanubrutinib in R/R MCL at #EHA2025 . Encouraging safety and antitumor activity at RP2D with ORR of 78% and a CR rate of 70%. At median DOR of 17.7 mo, estimate event-free DOR at 24 months was 84%. Moving on to Ph3 CELESTIAL-RRMCL #lymsm

What a great honor to present the updated data of BGB-11417-101 trial exploring #sonrotoclax + #zanubrutinib in R/R MCL at #EHA2025. Thanks BeOne Medicines for this great opportunity #hematology #lymphoma #lymsm

EHA 2025 - ECHO trial: nice to be part of an international effort thanks to our patients and wonderful team at FUNDALEU

Congratulations Nicholas Huntington, Jai Rautela and team on this very elegant work! CRISPR screens will definitely advance the field of NK and CAR-NK cell therapy. Looking forward to the clinical translation of the uncovered hits! #NK #CARNK #CRISPRscreen

Dr. Daisy Diaz presenting at #EHA2025 multiomics analysis of R/R CLL resistant to venetoclax and BTKis identifying multiple pathways affected. Also presented was preclinical work on a BCL2/BCL-xL degrader based off navitoclax able to overcome VEN/BTKi resistance #CLLsm

CONGRESS | #EHA2025 | PRESENTATION Raul Cordoba Raul Cordoba, MD, PhD Fundación Jiménez Díaz presents the first efficacy and safety results for epcoritamab in combination with R-ICE in patients with R/R DLBCL eligible for ASCT from the EPCORE NHL-2 trial (N = 31). Epcoritamab + R-ICE

Amazing presentation by Dr. Daniel Hodson on genomics of DLBCL to close #EHA2025 . Beautiful innovative preclinical modeling. His message: we need to all speak the same language between biologists, translational scientists and clinical researchers for breakthroughs in DLBCL.

#EHA25 #EHA2025 Thank you 🙏 #Milano 🇮🇹 for hosting us European Hematology Association | See you at #EHA2026 #EHA26 ! Claire Harrison Ruben A. Mesa, MD Nitin Jain Naval Daver, M.D. Joshua Zeidner MD Aditi Shastri, MD

CONGRESS | #18ICML | David A. Russler-Germain David Russler-Germain, MD/PhD Siteman Cancer Center discusses three identified Large B-cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs): LN, TEX, and FMAC, in which the LN archetype predicts the best outcomes following CD19 CAR T-cell therapy.

CONGRESS | #18ICML2025 | PRESENTATION L. Elizabeth Budde (L. Elizabeth Budde, M.D., Ph.D.), @CityofHope presents interim phase II MorningSun results of fixed-duration subcutaneous mosunetuzumab in patients with untreated high-tumor burden FL (N = 102). ORR was 87.3%, with 60.8% achieving

CONGRESS | #18ICML | PRESENTATION Michael Wang Michael Wang, MD MD Anderson Cancer Center discusses results from the SYMPATICO study of first-line ibrutinib plus venetoclax in patients with #MantleCellLymphoma who are ≥65 years or have TP53 mutations; concluding that this combination may be